NielsjeB schreef op 13 juni 2018 22:00:
Goldman Sachs Global Healthcare Conference - Gilead Sciences
cc.talkpoint.com/gold006/061218a_as/John McHutchison (CSO) vanaf 32:08, even puntsgewijs samengevat. Is maar een paar minuten, dus het luisteren zeker waard!
Q: could this be your cornerstone drug in autoimmune diseases?
A:
- we think it could be the cornerstone, the backbone
- acr20 not good enough (80% of your joints are not better), surely we can do better than that, that is our long-term goal [NB: met filgotinib of combo].
- most jak1-selective drug that has been shown independently by multiple academics
- we're excited about the programs in RA which accelerated quickly
but we're really excited about IBD, we could be the first JAK approved in CD and second in UC
- we want to get all our fase 3 data sets, we want to see if the safety profile continues to be differentiated with those large data sets
- we'll see where we go in terms of the filings etc.
- excited about the program
- the day we started the collaboration to now, the drug continues to appear to be more differentiated as we go on
- first data set second half of this year, other trials to follow